Physician profile
Victor Levitan
NPI 1912965401
$4,320.48
in general payments reported to CMS, 2019-2025
30 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $116 · 2023: $1,123 · 2024: $1,914 · 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,120 · Education: $84.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,119.81 |
| Education | $84.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $437.79 | 2023-2025 | |
| Novo Nordisk INC | $436.53 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $346.70 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $319.13 | 2023-2025 | |
| Glaxosmithkline, LLC. | $294.23 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $279.76 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $197.43 | 2023-2024 | Gemtesa |
| Lilly USA, LLC | $188.63 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $160.70 | 2023-2024 | Evenity, Prolia, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.37 | 2023-2024 | Trulance, Xifaxan |
| Exact Sciences Corporation | $146.83 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ibsa Pharma INC. | $146.59 | 2023-2025 | Licart, Tirosint, Tirosint |
| Idorsia Pharmaceuticals US INC | $135.19 | 2023-2025 | Quviviq, Quviviq |
| Astellas Pharma US INC | $127.06 | 2023-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.85 | 2023-2025 | Jardiance, Synjardy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $119.93 | 2024 | Quillichew Er, Dyanavel Xr, Quillivant |
| Esperion Therapeutics, INC. | $111.43 | 2024-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $94.25 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $78.97 | 2023-2025 | Seglentis, Livalo, Zoryve |
| Phathom Pharmaceuticals, INC. | $73.57 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $67.29 | 2023-2025 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $52.15 | 2023-2025 | Trintellix |
| Ardelyx, INC. | $51.37 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $44.73 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boston Scientific Corporation | $33.59 | 2025 | Watchman Flx |
| Corcept Therapeutics | $33.23 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $22.18 | 2024 | Rexulti |
| Noven Therapeutics, LLC | $16.30 | 2024 | Xelstrym |
| Amarin Pharma, INC. | $14.72 | 2023 | |
| Theracosbio, LLC | $12.98 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Levitan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.